Delayed recovery of destocked molecules
Two large commercial molecules under destocking may not return as expected; management declined to quantify value, creating uncertainty.
COHANCELIFESCIENCES / Q4-FY26 / risks
Keep the risk register visible.
Cohance Lifesciences · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Middle East logistics cost inflation
Geopolitical tensions have increased freight and raw material costs, expected to impact gross margins by 100-150 bps in Q1 FY27.
NJ Bio profitability timeline extended
NJ Bio's US facility expansion and bio conjugation capabilities will take >2 years to reach breakeven, delaying consolidated margin recovery.
Customer concentration in CDMO
Historical reliance on a few molecules led to revenue volatility; diversification is improving but still a risk.